Treatment of Menopausal Symptoms When Hormone Therapy Is Contraindicated

Abstract

Menopausal symptoms, particularly vasomotor symptoms (VMS) and genitourinary syndrome of menopause (GSM), significantly affect women's quality of life (QoL). While menopausal hormone therapy (MHT) is the most effective treatment, contraindications such as estrogen-sensitive cancers and thromboembolic conditions limit its use for many women. This review explores alternative nonhormonal treatments, including pharmacological options like selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, gabapentin, clonidine, and neurokinin receptor antagonists (e.g., fezolinetant), alongside nonpharmacological approaches such as lifestyle modifications, cognitive-behavioral therapy, and acupuncture. These alternatives, though less effective than MHT, provide critical options for women unable to use hormonal therapies. Emerging treatments like fezolinetant demonstrate promise in reducing VMS by addressing the underlying pathophysiology, but safety concerns, such as hepatotoxicity, require ongoing monitoring. GSM management includes therapies such as vaginal estrogens, prasterone, and ospemifene, with tailored approaches necessary for cancer survivors. Emphasis is placed on individualized care, better patient education, and continued research into the safety and efficacy of these therapies to improve the QoL for postmenopausal women.

Keywords

fezolinetant - genitourinary syndrome of menopause - menopause - nonhormone therapy - vasomotor symptoms

Publication History

Article published online:
02 September 2025

• References

• 1 Hirsch H, Manson JE. Menopausal symptom management in women with cardiovascular disease or vascular risk factors. Maturitas 2022; 161: 1-6
• 2 InterLACE Study Team. Variations in reproductive events across life: a pooled analysis of data from 505 147 women across 10 countries. Hum Reprod 2019; 34 (05) 881-893
• 3 Palacios S, Henderson VW, Siseles N, Tan D, Villaseca P. Age of menopause and impact of climacteric symptoms by geographical region. Climacteric 2010; 13 (05) 419-428
• 4 Nappi RE, Kroll R, Siddiqui E. et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause 2021; 28 (08) 875-882
• 5 Avis NE, Crawford SL, Greendale G. et al; Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175 (04) 531-539
• 6 Faubion SS, Enders F, Hedges MS. et al. Impact of menopause symptoms on women in the workplace. Mayo Clin Proc 2023; 98 (06) 833-845
• 7 Saarinen T, Savukoski SM, Pesonen P. et al. Climacteric status at age 46 is associated with poorer work ability, lower 2-year participation in working life, and a higher 7-year disability retirement rate: a Northern Finland Birth Cohort 1966 study. Menopause 2024; 31 (04) 275-281
• 8 Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; 2004 (04) CD002978
• 9 Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the women's health initiative. Menopause 2012; 19 (06) 616-621
• 10 Crawford SL, Crandall CJ, Derby CA. et al. Menopausal hormone therapy trends before versus after 2002: impact of the women's health initiative study results. Menopause 2018; 26 (06) 588-597
• 11 Weller SC, Davis JW, Porterfield L, Chen L, Wilkinson G. Hormone exposure and venous thromboembolism in commercially insured women aged 50 to 64 years. Res Pract Thromb Haemost 2023; 7 (03) 100135
• 12 “The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2023 nonhormone therapy position statement of the North American Menopause Society. Menopause 2023; 30 (06) 573-590
• 13 Faubion SS, Crandall CJ, Davis L. et al; “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause 2022; 29 (07) 767-794
• 14 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
• 15 Marino JL, Saunders CM, Emery LI, Green H, Doherty DA, Hickey M. Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history. Menopause 2014; 21 (03) 267-274
• 16 Pistilli B, Paci A, Ferreira AR. et al. Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk. J Clin Oncol 2020; 38 (24) 2762-2772
• 17 De Jong A, Von Wachenfeldt A, Nyström L, Andersson A. Adherence to adjuvant endocrine therapy after breast cancer in Sweden - a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences. Acta Oncol 2024; 63: 901-908
• 18 Davis SR, Pinkerton J, Santoro N, Simoncini T. Menopause-biology, consequences, supportive care, and therapeutic options. Cell 2023; 186 (19) 4038-4058
• 19 Carroll DG, Lisenby KM, Carter TL. Critical appraisal of paroxetine for the treatment of vasomotor symptoms. Int J Womens Health 2015; 7: 615-624
• 20 Stearns V, Slack R, Greep N. et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005; 23 (28) 6919-6930
• 21 Stearns V, Johnson MD, Rae JM. et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95 (23) 1758-1764
• 22 Kelly CM, Juurlink DN, Gomes T. et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010; 340 (7742) c693
• 23 Bradbury M, Hutton B, Beltran-Bless AA. et al. Time to update evidence-based guideline recommendations about concurrent tamoxifen and antidepressant use? A systematic review. Clin Breast Cancer 2022; 22 (03) e362-e373
• 24 Barton DL, LaVasseur BI, Sloan JA. et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010; 28 (20) 3278-3283
• 25 Freeman EW, Guthrie KA, Caan B. et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011; 305 (03) 267-274
• 26 Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005; 105 (01) 161-166
• 27 Ramaswami R, Villarreal MD, Pitta DM, Carpenter JS, Stebbing J, Kalesan B. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2015; 152 (02) 231-237
• 28 Joffe H, Guthrie KA, LaCroix AZ. et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014; 174 (07) 1058-1066
• 29 Sproule BA, Hazra M, Pollock BG. Desvenlafaxine succinate for major depressive disorder. Drugs Today (Barc) 2008; 44 (07) 475-487
• 30 Suvanto-Luukkonen E, Koivunen R, Sundström H. et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005; 12 (01) 18-26
• 31 Bala A, Nguyen HMT, Hellstrom WJG. Post-SSRI sexual dysfunction: a literature review. Sex Med Rev 2018; 6 (01) 29-34
• 32 Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev 2019; 1 (01) CD007076
• 33 Guttuso Jr T, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003; 101 (02) 337-345
• 34 Loprinzi CL, Qin R, Balcueva EP. et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 2010; 28 (04) 641-647
• 35 Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction 2016; 111 (07) 1160-1174
• 36 Tran S, Hickey M, Saunders C, Ramage L, Cohen PA. Nonpharmacological therapies for the management of menopausal vasomotor symptoms in breast cancer survivors. Support Care Cancer 2021; 29 (03) 1183-1193
• 37 Richardson K, Fox C, Maidment I. et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ 2018; 361: k1315
• 38 Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol 2013; 34 (03) 211-227
• 39 Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs 2021; 30 (07) 681-694
• 40 Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study. J Clin Psychopharmacol 2014; 34 (02) 199-204
• 41 Lederman S, Ottery FD, Cano A. et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet 2023; 401 (10382): 1091-1102
• 42 Johnson KA, Martin N, Nappi RE. et al. Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT. J Clin Endocrinol Metab 2023; 108 (08) 1981-1997
• 43 Cano A, Nappi RE, Santoro N. et al. Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials. BJOG 2024; 131 (09) 1296-1305
• 44 FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause | FDA. Accessed January 24, 2025 at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due
• 45 Di Maio M, Baratelli C, Bironzo P. et al. Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2018; 124: 21-28
• 46 Pinkerton JV, Simon JA, Joffe H. et al. Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials. JAMA 2024; 332 (16) 1343-1354
• 47 Simon JA, Anderson RA, Ballantyne E. et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause 2023; 30 (03) 239-246
• 48 Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA) - results from an international survey. Climacteric 2012; 15 (01) 36-44
• 49 Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: women's health initiative. Maturitas 2004; 49 (04) 292-303
• 50 Lester J, Pahouja G, Andersen B, Lustberg M. Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. J Pers Med 2015; 5 (02) 50-66
• 51 Faubion SS, Kingsberg SA, Clark AL. et al; The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. Menopause 2020; 27 (09) 976-992
• 52 ACOG Committee Opinion No. ACOG committee opinion no. 734 summary: the role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding. Obstet Gynecol 2018; 131 (05) 945-946
• 53 ACOG. Accessed January 25, 2025 at: https://www.acog.org/-/media/project/acog/acogorg/clinical/files/clinical-consensus/articles/2021/12/treatment-of-urogenital-symptoms-in-individuals.pdf?rev=42989a66fa1c4daaa148a3853d27bb05&hash=C03514B3BD087D1FE7A80E6E95A545BA
• 54 Faubion SS, Larkin LC, Stuenkel CA. et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from the North American Menopause Society and the International Society for the Study of Women's Sexual Health. Menopause 2018; 25 (06) 596-608
• 55 ACOG Committee Opinion No. ACOG committee opinion no. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 2016; 127 (03) e93-e96
• 56 Labrie F, Archer DF, Koltun W. et al; VVA Prasterone Research Group. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2016; 23 (03) 243-256
• 57 Pavlović RT, Janković SM, Milovanović JR. et al. The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis. Clin Breast Cancer 2019; 19 (06) e731-e740
• 58 Chambers LM, Herrmann A, Michener CM, Ferrando CA, Ricci S. Vaginal estrogen use for genitourinary symptoms in women with a history of uterine, cervical, or ovarian carcinoma. Int J Gynecol Cancer 2020; 30 (04) 515-524
• 59 Sussman TA, Kruse ML, Thacker HL, Abraham J. Managing genitourinary syndrome of menopause in breast cancer survivors receiving endocrine therapy. J Oncol Pract 2019; 15 (07) 363-370
• 60 Crandall CJ, Diamant A, Santoro N. Safety of vaginal estrogens: a systematic review. Menopause 2020; 27 (03) 339-360
• 61 McVicker L, Labeit AM, Coupland CAC. et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol 2024; 10 (01) 103-108
• 62 Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst 2022; 114 (10) 1347-1354
• 63 Wurz GT, Kao CJ, DeGregorio MW. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause. Clin Interv Aging 2014; 9: 1939-1950
• 64 Pharmacology Update. Ospemifene Tablets (Osphena) |… | Relias Media. Accessed January 25, 2025 at: https://www.reliasmedia.com/articles/65088-pharmacology-update-ospemifene-tablets-osphena
• 65 Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric 2015; 18 (02) 226-232
• 66 Portman DJ, Bachmann GA, Simon JA. Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013; 20 (06) 623-630
• 67 Bachmann GA, Komi JO. Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010; 17 (03) 480-486
• 68 Archer DF, Simon JA, Portman DJ, Goldstein SR, Goldstein I. Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause. Expert Rev Endocrinol Metab 2019; 14 (05) 301-314
• 69 Qu Q, Zheng H, Dahllund J. et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000; 141 (02) 809-820
• 70 Maffei S, Guiducci L. Effect of ospemifene on densitometric and plasma bone metabolism biomarkers in postmenopausal women reporting vulvar and vaginal atrophy (VVA). J Clin Med 2022; 11 (21) 6316
• 71 de Villiers TJ, Altomare C, Particco M, Gambacciani M. Effects of ospemifene on bone in postmenopausal women. Climacteric 2019; 22 (05) 442-447
• 72 Senshio | European Medicines Agency (EMA). Accessed January 25, 2025 at: https://www.ema.europa.eu/en/medicines/human/EPAR/senshio
• 73 Nordstrom BL, Cai B, De Gregorio F. et al. Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study. Ther Adv Drug Saf 2022 ;13:20420986221135931
• 74 Danan ER, Sowerby C, Ullman KE. et al. Hormonal treatments and vaginal moisturizers for genitourinary syndrome of menopause : a systematic review. Ann Intern Med 2024; 177 (10) 1400-1414
• 75 Archer DF, Labrie F, Bouchard C. et al; VVA Prasterone Group. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause 2015; 22 (09) 950-963
• 76 Hickey M, Basu P, Sassarini J. et al. Managing menopause after cancer. Lancet 2024; 403 (10430): 984-996
• 77 Bohbot JM, de Belilovsky C, Brami G, Mares P. Efficacy of a medical device containing liposomal hyaluronic acid against vulvo-vaginal dryness. Gynécol Obstét Fertil 2015; 43 (06) 437-442
• 78 Palacios S. Non-hormonal approaches for the treatment of vulvovaginal atrophy: the choice between hyaluronic acid and glycerin. Gynecol Endocrinol 2020; 36 (10) 847-848
• 79 Dodin S, Blanchet C, Marc I. et al. Acupuncture for menopausal hot flushes. Cochrane Database Syst Rev 2013; 2013 (07) CD007410
• 80 Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2014; 2014 (11) CD006108
• 81 Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002; 137 (10) 805-813
• 82 Trémollieres FA, Chabbert-Buffet N, Plu-Bureau G. et al. Management of postmenopausal women: Collège National des Gynécologues et Obstétriciens Français (CNGOF) and Groupe d'Etude sur la Ménopause et le Vieillissement (GEMVi) Clinical Practice Guidelines. Maturitas 2022; 163: 62-81
• 83 Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev 2013; 2013 (12) CD001395
• 84 Kenda M, Glavač NK, Nagy M, Sollner Dolenc M. On Behalf Of The Oemonom. Herbal products used in menopause and for gynecological disorders. Molecules 2021; 26 (24) 7421
• 85 Mension E, Alonso I, Anglès-Acedo S. et al. Effect of fractional carbon dioxide vs sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause: the LIGHT randomized clinical trial. JAMA Netw Open 2023; 6 (02) e2255697-e2255697
• 86 Guo JZ, Souders C, McClelland L. et al. Vaginal laser treatment of genitourinary syndrome of menopause: does the evidence support the FDA safety communication?. Menopause 2020; 27 (10) 1177-1184
• 87 Mension E, Alonso I, Tortajada M. et al. Vaginal laser therapy for genitourinary syndrome of menopause - systematic review. Maturitas 2022; 156: 37-59
• 88 Pan M, Zhou J, Pan X, Wang J, Qi Q, Wang L. Drugs for the treatment of postmenopausal symptoms: Hormonal and non-hormonal therapy. Life Sci 2023; 312: 121255